Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Amortization of discount on short-term investments | (4,217) | (2,966) |
| Unrealized foreign exchange loss (gain) | 190 | (224) |
| Depreciation | 44 | 25 |
| Stock-based compensation | 72,791 | 11,096 |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (11,014) | 1,850 |
| Other assets | (1,026) | (1,419) |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's D&A?
- Summit Therapeutics (SMMT) reported D&A of $44K in Q1 2026.
- How has Summit Therapeutics's D&A changed year-over-year?
- Summit Therapeutics's D&A increased by 76.0% year-over-year, from $25K to $44K.
- What is the long-term trend for Summit Therapeutics's D&A?
- Over 4 years (2021 to 2025), Summit Therapeutics's D&A has grown at a -18.4% compound annual growth rate (CAGR), from $330K to $146K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Summit Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude